Research programme: barrett's oesophagus therapeutics - EsoCap
Latest Information Update: 29 Jan 2022
At a glance
- Originator Upadia Holding
- Developer EsoCap AG; Upadia Holding
- Class Monoclonal antibodies
- Mechanism of Action Bone morphogenetic protein 2 inhibitors; Bone morphogenetic protein-4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Barrett's oesophagus
Most Recent Events
- 18 Jan 2022 Early research in Barrett's oesophagus in Switzerland (PO)
- 10 Jan 2022 EsoCap AG and Upadia Holding enters into an antibody licensing agreement for the development of targeted therapeutics to treat Barrett’s oesophagus
- 10 Jan 2022 Pharmacodynamics data from preclinical study in Barret's oesophagus released by EsoCap AG